The state of Massachusetts currently has 157 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT04925284
Recruiting
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab to subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Exelixis Clinical Site #25, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Register for Updates
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701
Recruiting
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer, Non-small Cell Lung Carcinoma
Register for Updates
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512
Recruiting
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
NCT04593277
Recruiting
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. By improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
Register for Updates
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705
Recruiting
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
A Study of XMT-1660 in Participants With Solid Tumors
NCT05377996
Recruiting
A Study of XMT-1660 in Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +1 locations
Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Research Site, Boston, Massachusetts
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587
Recruiting
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Dana Faber Cancer Institute, Boston, Massachusetts
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
Register for Updates
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT02290834
Recruiting
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
Gender:
Female
Ages:
60 years and above
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Impaired Cognition, Chemo-brain, Breast Cancer
Register for Updates
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03990896
Recruiting
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT04443348
Recruiting
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: Radiation Therapy (RT) Immunotherapy: Pembrolizumab (MK-3475) Chemotherapies: Paclitaxel Doxorubicin (also called Adriamycin) Cyclophosphamide Carboplatin (optional, and in TN only) Capecitabine (opti... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Register for Updates
Sacituzumab Govitecan In TNBC
NCT04230109
Recruiting
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: Sacituzumab govitecan (SG) Pembrolizumab (combination therapy with SG)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +4 locations
Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Register for Updates